tipifarnib has been researched along with Hematologic Neoplasms in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feldman, EJ | 2 |
| Karp, JE; Lancet, JE | 2 |
| Cortes, J; Jabbour, E; Kantarjian, H | 2 |
| Berk, S; Gajewski, TF; Harlin, H; Karrison, T; Larson, RA; Odenike, OM; Ratain, MJ; Sprague, E; Stock, W; Zimmerman, TM | 1 |
| Karp, JE | 2 |
| Harousseau, JL | 1 |
| Hayashi, Y | 1 |
| Armand, JP; Burnett, AK; Drach, J; Harousseau, JL; Löwenberg, B; San Miguel, J | 1 |
| Iacobucci, I; Martinelli, G; Ottaviani, E; Paolini, S | 1 |
10 review(s) available for tipifarnib and Hematologic Neoplasms
| Article | Year |
|---|---|
Farnesyltransferase inhibitors in myelodysplastic syndrome.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Farnesyltranstransferase; Gastrointestinal Diseases; Genes, ras; Hematologic Neoplasms; Humans; Middle Aged; Myelodysplastic Syndromes; Piperidines; Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Treatment Outcome | 2006 |
Farnesyl transferase inhibitors in myeloid malignancies.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myeloid, Acute; Models, Biological; Myeloproliferative Disorders; Piperazines; Pyrimidines; Quinolones; ras Proteins; Signal Transduction | 2003 |
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Imidazoles; Piperidines; Pyridines; Quinolones; ras Proteins; Signal Transduction | 2004 |
Farnesyltransferase inhibitors in myelodysplastic syndrome.
Topics: Acute Disease; Aged; Alkyl and Aryl Transferases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Enzyme Inhibitors; Farnesyltranstransferase; Genes, ras; Hematologic Neoplasms; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Pyridines; Quinolones; Remission Induction; Signal Transduction; Treatment Outcome | 2005 |
Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Quinolones | 2005 |
Farnesyltransferase inihibitors in hematologic malignancies.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Piperidines; Pyridines; Quinolones; Signal Transduction | 2007 |
Clinical activity of tipifarnib in hematologic malignancies.
Topics: Animals; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Myelodysplastic Syndromes; Quinolones | 2007 |
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hematologic Neoplasms; Humans; Pyrazines; Quinolones | 2007 |
Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Clinical Trials as Topic; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Quinolones; Signal Transduction | 2008 |
Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.
Topics: Alkyl and Aryl Transferases; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Quinolones; Signal Transduction | 2001 |
1 trial(s) available for tipifarnib and Hematologic Neoplasms
| Article | Year |
|---|---|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Analysis of Variance; Biological Availability; Blotting, Western; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Risk Assessment; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2004 |
2 other study(ies) available for tipifarnib and Hematologic Neoplasms
| Article | Year |
|---|---|
Farnesyl transferase inhibition in hematologic malignancies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Quinolones | 2005 |
[Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biomarkers, Tumor; Child; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Loss of Heterozygosity; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Quinolones; Rituximab; Tretinoin | 2007 |